Acute Myeloid Leukemia Therapeutics
1. Daurismo patent expiration
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >=...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8148401 | PFIZER | Benzimidazole derivatives |
Jan, 2031
(5 years from now) | |
| US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(10 years from now) | |
| US11891372 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(10 years from now) | |
| US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 21, 2023 |
| Orphan Drug Exclusivity(ODE-224) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: 21 November, 2022
Market Authorisation Date: 21 November, 2018
Dosage: TABLET
More Information on Dosage
DAURISMO family patents
2. Grafapex patent expiration
Treatment: Administering treosulfan as a preparative regimen for allogeneic stem cell transplantation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7199162 | MEDEXUS | Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
Mar, 2026
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2030 |
| Orphan Drug Exclusivity(ODE-513) | Jan 21, 2032 |
| Orphan Drug Exclusivity(ODE-514) | Jan 21, 2032 |
Drugs and Companies using TREOSULFAN ingredient
NCE-1 date: 21 January, 2029
Market Authorisation Date: 21 January, 2025
Dosage: POWDER
More Information on Dosage
GRAFAPEX family patents
3. Idhifa patent
expiration
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
IDHIFA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512107 | BRISTOL MYERS SQUIBB | Therapeutically active compositions and their methods of use |
Jan, 2033
(7 years from now) | |
| US10093654 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(8 years from now) | |
| US9732062 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Sep, 2034
(8 years from now) | |
| US9738625 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10294215 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Dosage: TABLET
More Information on Dosage
IDHIFA family patents
4. Revuforj patent expiration
Treatment: Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2a gene (kmt2a) translocation in adult and pediatric patients 1 year and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10683302 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11479557 | SYNDAX | Inhibitors of the menin-MLL interaction |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2029 |
| Orphan Drug Exclusivity(ODE-502) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-504) | Nov 15, 2031 |
| Orphan Drug Exclusivity(ODE-505) | Nov 15, 2031 |
Drugs and Companies using REVUMENIB CITRATE ingredient
NCE-1 date: 15 November, 2028
Market Authorisation Date: 15 November, 2024
Dosage: TABLET
More Information on Dosage
REVUFORJ family patents
5. Rezlidhia patent expiration
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a can...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9834539 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US12275715 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US10532047 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US12053463 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11013734 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11013733 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(13 years from now) | |
| US11497743 | RIGEL PHARMS | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(13 years from now) | |
| US11376246 | RIGEL PHARMS | Inhibiting mutant IDH-1 |
May, 2039
(13 years from now) | |
| US11738018 | RIGEL PHARMS | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(13 years from now) | |
| US10959994 | RIGEL PHARMS | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(13 years from now) | |
| US10414752 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US10550098 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| US11723905 | RIGEL PHARMS | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(13 years from now) | |
| US11498913 | RIGEL PHARMS | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Dosage: CAPSULE
More Information on Dosage
REZLIDHIA family patents
6. Rydapt patent expiration
Treatment: Treatment of adult patients with newly diagnosed acute myeloid leukemia (aml) who are flt3 mutation-positive, in combination with standard c...
RYDAPT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8222244 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2022
(3 years ago) | |
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(4 years from now) | |
| US7973031 | NOVARTIS | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Dosage: CAPSULE
How can I launch a generic of RYDAPT before it's drug patent expiration?
More Information on Dosage
RYDAPT family patents
7. Tibsovo patent expiration
Treatment: A method of treating a cancer characterized by an idh1 mutation wherein the cancer is relapsed or refractory myelodysplastic syndromes; A method for treating newly diagnosed aml with ivosidenib and az...
TIBSOVO IPR and PTAB Proceedings
Can you believe TIBSOVO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(7 years from now) | |
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11667673 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(4 years from now) | |
| US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(7 years from now) | |
| US10653710 | SERVIER | Combination therapy for treating malignancies |
Oct, 2036
(10 years from now) | |
| US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(13 years from now) | |
| US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-816) | May 02, 2022 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-893) | May 25, 2025 |
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Dosage: TABLET
How can I launch a generic of TIBSOVO before it's drug patent expiration?
More Information on Dosage
TIBSOVO family patents
8. Vanflyta patent expiration
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8883783 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(1 year, 2 months from now) | |
| US7820657 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Sep, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585892 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(1 year, 2 months from now) | |
| US9555040 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
May, 2030
(4 years from now) | |
| US8836218 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Mar, 2030
(4 years from now) | |
| US8357690 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Feb, 2031
(5 years from now) | |
| US8129374 | DAIICHI SANKYO INC | Method of using imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(1 year, 2 months from now) | |
| US7968543 | DAIICHI SANKYO INC | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
Aug, 2029
(3 years from now) | |
| US8865710 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
Aug, 2029
(3 years from now) | |
| US9675549 | DAIICHI SANKYO INC | Tablet containing composite with cyclodextrin |
Sep, 2033
(7 years from now) | |
| US8557810 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
Drugs and Companies using QUIZARTINIB DIHYDROCHLORIDE ingredient
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Dosage: TABLET
More Information on Dosage
VANFLYTA family patents
9. Venclexta patent expiration
Treatment: Treatment of patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll), with or without 17p deletion, who have received at least one prior therapy; Treatment of adults with ...
VENCLEXTA's oppositions filed in EPO
VENCLEXTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546399 | ABBVIE | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Jun, 2031
(5 years from now) | |
| US10730873 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Nov, 2031
(5 years from now) | |
| US8722657 | ABBVIE | Salts and crystalline forms of an apoptosis-inducing agent |
Jan, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9174982 | ABBVIE | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
May, 2030
(4 years from now) | |
| US11413282 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US9539251 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(7 years from now) | |
| US11369599 | ABBVIE | Melt-extruded solid dispersions containing an apoptosis-inducing agent |
May, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Dosage: TABLET
How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage
VENCLEXTA family patents
10. Xospata patent expiration
Treatment: Treatment of acute myeloid leukemia (aml)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Nov, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(4 years from now) | |
| US11938133 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11944620 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938130 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938131 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| US11938132 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
| Orphan Drug Exclusivity(ODE-222) | Nov 28, 2025 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Dosage: TABLET
How can I launch a generic of XOSPATA before it's drug patent expiration?
More Information on Dosage
XOSPATA family patents